For example, some researches have already found that immune biomarkers include programmed cell death-1 (PD-1), infiltration of the CD8+ T-cell, PD ligand 1 (PD-L1) expression, and tumor mutation burden (TMB) for immunotherapy in CRC. This evidence concerns the gene CD274 and neoplasm.